← Back to Search

Cannabinoids

TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg) for Human Immunodeficiency Virus Infection

Phase 2
Waitlist Available
Led By Cecilia Costiniuk, MD, MSc
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0-12
Awards & highlights

Study Summary

This trial is testing whether oral cannabinoids are safe and tolerated in people with HIV, and whether they may reduce HIV-associated inflammation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0-12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0-12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
WHO toxicity scale
Secondary outcome measures
Change in immune cell profile
Change in plasma inflammatory markers
Change in proportion activated CD4 and CD8 T cell lymphocytes

Trial Design

2Treatment groups
Experimental Treatment
Group I: 2) CBD aloneExperimental Treatment1 Intervention
TN-C200M2 oral capsules (CBD 200 mg)
Group II: 1) THC and CBD combinedExperimental Treatment1 Intervention
TN-TC11M2 oral capsules (THC 2.5 mg / CBD 2.5 mg)

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
443 Previous Clinical Trials
159,488 Total Patients Enrolled
TilrayIndustry Sponsor
7 Previous Clinical Trials
235 Total Patients Enrolled
CIHR Canadian HIV Trials NetworkNETWORK
40 Previous Clinical Trials
6,429 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Cannabinoids in PLWHIV on Effective ART
Cecilia Costiniuk 2021. "Cannabinoids in PLWHIV on Effective ART". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03550352.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top